Illumina, Inc. vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Illumina, Inc. trades at $275.34 (market cap $39.95B), while JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M). The key difference: Illumina, Inc. is far larger — about 105.5× JPMorgan Diversified Return International Eqty ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| ILMN | JPIN | |
|---|---|---|
Market Cap | $39.95B | $378.77M |
Volume | 3,169,503 | 13,861 |
Sector | Health | — |
52-Week High | $293.69 | $77.80 |
52-Week Low | $91.00 | $64.96 |
Typical Hold Time | 83 Days | 120 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
JPIN trades at $73.01, up 0.1% on the day, but technical indicators signal a bearish trend with 21 sell signals versus 2 buy signals. The ETF exhibits oversold conditions with RSI readings below 25, while moving averages and ADX reinforce downward momentum. A dividend of $0.51 is scheduled for payment in September 2026, offering income potential amid weak price action.
The outlook remains cautious due to strong bearish technical pressure, though oversold RSI levels may attract contrarian buyers. Risks include persistent selling pressure and reliance on international equity markets. Investment appeal hinges on dividend yield and potential mean reversion if broader market sentiment improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →